Quest launches OVA1 ovarian cancer test in US
This article was originally published in Clinica
Executive Summary
Quest Diagnostics has launched its OVA1 ovarian cancer blood test in the US. The diagnostic, which the firm developed with Vermillion, is designed to determine whether a pelvic mass is malignant or benign.